Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy
A Randomized Clinical Trial

Di Qiu, MD; Xing-Ming Wang, MD, PhD; Jin-Jin Yang, MD; Sai Chen, MD; Cai-Bao Yue, MD; Kenji Hashimoto, PhD; Jian-Jun Yang, MD, PhD

Abstract

IMPORTANCE Postoperative sleep disturbance (PSD) is common in patients after surgery.

OBJECTIVE To examine the effect of intraoperative esketamine infusion on the incidence of PSD in patients who underwent gynecological laparoscopic surgery.

DESIGN, SETTING, AND PARTICIPANTS This single-center, double-blind, placebo-controlled randomized clinical trial was conducted from August 2021 to April 2022 in the First Affiliated Hospital of Zhengzhou University in China. Participants included patients aged 18 to 65 years with an American Society of Anesthesiologist Physical Status classification of I to III (with I indicating a healthy patient, II a patient with mild systemic disease, and III a patient with severe systemic disease) who underwent gynecological laparoscopic surgery. Patients were randomly assigned to either the esketamine group or control group. Data were analyzed using the per protocol principle.

INTERVENTIONS Patients in the esketamine group received a continuous infusion of esketamine, 0.3 mg/kg/h, intraoperatively. Patients in the control group received an equivalent volume of saline.

MAIN OUTCOMES AND MEASURES The primary outcome was the incidence of PSD on postoperative days (PODs) 1 and 3. Postoperative sleep disturbance was defined as a numeric rating scale score of 6 or higher or an Athens Insomnia Scale score of 6 points or higher. The secondary outcomes included postoperative anxiety and depression scores using the Hospital Anxiety and Depression Scale, postoperative pain using the visual analog scale, postoperative hydromorphone consumption, and risk factors associated with PSD.

RESULTS A total of 183 female patients were randomized to the control group (n = 91; median [IQR] age, 45 [35-49] years) and the esketamine group (n = 92; median [IQR] age, 43 [32-49] years). The incidence of PSD in the esketamine group was significantly lower than in the control group on POD 1 (22.8% vs 44.0%; odds ratio [OR], 0.38 [95% CI, 0.20-0.72]; P = .002) and POD 3 (7.6% vs 19.8%; OR, 0.33 [95% CI, 0.13-0.84]; P = .02). There were no differences in postoperative depression and anxiety scores between the 2 groups. Postoperative hydromorphone consumption in the first 24 hours (3.0 [range, 2.8-3.3] mg vs 3.2 [range, 2.9-3.4] mg; P = .04) and pain scores on movement (3 [3-4] vs 4 [3-5] points; P < .001) were significantly lower in the esketamine group than in the control group. On multivariable logistic regression, preoperative depression (OR, 1.31; 95% CI, 1.01-1.70) and anxiety (OR, 1.67; 95% CI, 1.04-2.60) scores, duration of anesthesia (OR, 1.04; 95% CI, 1.00-1.08), and postoperative pain score (OR, 1.92; 95% CI, 1.24-2.96) were identified as risk factors associated with PSD.

(continued)
CONCLUSIONS AND RELEVANCE  Results of this trial showed the prophylactic effect of intraoperative esketamine infusion on the incidence of PSD in patients who underwent gynecological laparoscopic surgery. Further studies are needed to confirm these results.

TRIAL REGISTRATION  Chinese Clinical Trial Registry Identifier: ChiCTR2100048587


Abstract (continued)

Introduction

Postoperative sleep disturbance (PSD), which can be in the form of sleep deprivation, circadian disruption, and abnormal architecture, occurs in 15% to 72% of patients after surgery. It is associated with several factors, including older age, female sex, postoperative pain and anxiety, postoperative nausea and vomiting, and maladaptation to the ward environment. Postoperative sleep disturbance could lead to postoperative delirium and cognitive impairment, exacerbate acute postoperative pain, and delay postoperative recovery. Pharmacological interventions, such as short-acting non-benzodiazepine zolpidem and melatonin, have often been used to improve postoperative sleep quality. However, to our knowledge, there are no studies regarding prophylactic agents for PSD.

(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, is a racemic mixture of equal amounts of (R)-ketamine (ie, arketamine) and (S)-ketamine (ie, esketamine), with esketamine having a greater affinity for the NMDAR. A subanesthetic dose of (R,S)-ketamine (0.5 mg/kg, 40-minute intravenous [IV] infusion) is known to produce rapid-acting and sustained antidepressant actions in patients with major depressive disorder (MDD) resistant to treatment. Esketamine is used for anesthesia in some countries, including China. Subanesthetic doses (0.2 and 0.4 mg/kg, IV infusion) of esketamine have demonstrated rapid and robust antidepressant efficacy in patients with treatment-resistant MDD, although it had transient psychotomimetic and dissociative adverse effects. In 2019, an esketamine nasal spray (Johnson & Johnson) was approved in the US and Europe for treatment-resistant depression.

Postoperative sleep disturbance is often seen alongside depression in patients after surgery. In addition to its antidepressant actions, (R,S)-ketamine infusion has been demonstrated to improve sleep disturbance in patients with MDD and sleeping problems, suggesting the potential of (R,S)-ketamine for sleep disturbance. It has been suggested that the antidepressant effect of (R,S)-ketamine is connected with the neurobiological structure of the wake, sleep, and circadian rhythms. However, it is unknown whether IV infusions of low-dose esketamine intraoperatively can reduce the incidence of PSD. This trial aimed to examine the effect of intraoperative esketamine infusion on PSD in patients who underwent gynecological laparoscopic surgery.

Methods

Study Design

This prospective, double-blind, placebo-controlled randomized clinical trial was approved by the Institutional Scientific Research and Clinical Trials Ethics Committee of the First Affiliated Hospital of Zhengzhou University. The trial protocol is provided in Supplement 1. The protocol was explained to patients before the trial started, and written informed consent was obtained from all participants. We followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

The trial enrolled patients who were aged 18 to 65 years, had an American Society of Anesthesiologist (ASA) Physical Status classification of I to III (I indicates a healthy patient, II indicates a patient with mild systemic disease, and III indicates a patient with severe systemic disease), and

Downloaded From: https://jamanetwork.com/ on 12/08/2022
underwent gynecological laparoscopic surgery from August 2021 to April 2022 in the First Affiliated Hospital of Zhengzhou University in China. The exclusion criteria were as follows: (1) patient refusal to participate in the study, (2) body mass index (calculated as weight in kilograms divided by height in meters squared) higher than 30, (3) preoperative Pittsburgh Sleep Quality Index (PSQI) higher than 7, (4) recent history of drug abuse, (5) contraindications or allergy to esketamine, (6) cognitive dysfunction or inability to communicate, and (7) inability to use a patient-controlled IV analgesia pump. Race and ethnicity data were not collected because all trial participants were Han Chinese.

Patients were randomly assigned in a 1:1 ratio to receive either esketamine infusion, 0.3 mg/kg/h (Jiangsu Hengrui Pharmaceutical Co Ltd), or an equivalent volume of saline (Figure 1) using a computer-generated randomization table. For allocation concealment, group assignments were placed in sealed envelopes, which were sequentially handed to a nurse who was not involved in the study. Both esketamine and saline were prepared in identical 20-mL syringes by the same nurse. Anesthesiologists (D.Q., S.C., Jin-Jin Y.) who were involved in patient management and had participated in the postoperative follow-up were blinded to the group assignment. Esketamine, 50 mg, was diluted to a total of 20 mL with saline solution. Group assignments were not revealed until patients were discharged from the hospital.

**Anesthesia and Postoperative Analgesia Management**

Routine intraoperative monitoring was established, including pulse oximetry, electrocardiography, and noninvasive blood pressure measurement. Anesthesia was induced with etomidate, 0.2 mg/kg; alfentanil, 40-50 μg/kg; and then rocuronium, 0.9 mg/kg, to facilitate the insertion of a laryngeal mask airway (AuraGain; Ambu). Anesthesia was maintained with remifentanil, 0.1-0.2 μg/kg/min, and 2% sevoflurane in 50% oxygen, 2 L/min, and the remifentanil infusion rate was titrated to keep the heart rate and arterial blood pressure within 20% of baseline. Palonosetron, 0.25 mg, was intravenously administered at the end of the surgery to prevent postoperative nausea and vomiting. After completing surgery, the laryngeal mask was pulled out when adequate muscle strength was established. Postoperative pain was managed using hydromorphone, 0.2 mg/kg in 200 mL saline, by a patient-controlled IV analgesia pump: background infusion 2 mL/h for 48 hours, bolus 2 mL, lockout time 10 minutes. Flurbiprofen axetil, 50 mg, was intravenously administered as a rescue analgesic if the pain score was greater than 4.

**Figure 1. Participant Flowchart**

200 Assessed for eligibility

- 16 Excluded
  - 5 Contraindications or allergy to esketamine
  - 4 Did not agree to use patient-controlled analgesia pump
  - 3 Refused to participate
  - 2 PSQI score >7
  - 1 BMI >30
  - 1 Recent history of drug abuse

184 Randomized

- 92 Allocated to and received normal saline
  - 1 Lost to follow-up

- 92 Allocated to and received esketamine

91 Analyzed

92 Analyzed
Outcome Measurements

Postoperative sleep quality was evaluated using the numeric rating scale (NRS) and Athens Insomnia Scale (AIS). Postoperative pain scores were evaluated using the visual analog scale (VAS). Anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale (HADS) on preoperative day 1 and on postoperative days (PODs) 1 and 3.

The primary outcome was the incidence of PSD, which was evaluated using the NRS and AIS on PODs 1 and 3. Postoperative sleep disturbance was defined as having an NRS score of 6 or higher or AIS score of 6 points or higher, indicating that sleep was repeatedly interrupted throughout the night, or even worse.22,23 The secondary outcomes included postoperative pain scores at rest and on movement at 24 hours and 48 hours (using VAS), postoperative hydromorphone consumption in the first 24 hours and total consumption within 48 hours, anxiety and depression scores on PODs 1 and 3 (using HADS), and the risk factors associated with PSD.

The NRS score ranges from 0 to 10, wherein 0 represents excellent or good sleep and 10 represents the inability to fall asleep all night. The AIS is a self-rated psychometric questionnaire to quantify sleep difficulties according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision criteria.24 The AIS consists of 8 items: waking up at night, sleep induction, final awakening, total sleep duration, sleep quality, well-being, functional ability, and daytime sleepiness. The AIS score ranges from 0 to 24 points, and a total score of 6 points or higher indicates a diagnosis of insomnia.

The VAS score ranges from 0 (indicating no pain) to 10 (indicating intolerable pain) points. The HADS consists of 14 questions, with 7 items each for the anxiety and depression subscales. The score for each item ranges from 0 to 3 points, and scores are summed to yield a separate score for anxiety (HADS-A) and depression (HADS-D). Scores of 8 points or higher are diagnosed as depression or anxiety.

Postoperative hydromorphone consumption as well as postoperative complications, including nausea and vomiting, dizziness, itching, and nightmares, were noted and treated accordingly. In addition, surgery and anesthesia duration, consumption of intraoperative remifentanil, estimated infusion volume, blood loss and urine output, laryngeal mask removal time (the time from the end of surgery to airway removal of laryngeal mask), and length of stay in the postanesthesia care unit were also recorded.

Statistical Analysis

The estimated sample size was calculated from the results of a preliminary study, wherein the incidence of PSD was 40% in gynecological laparoscopic surgery on POD 1. The expected effect size was calculated to detect a 50% incidence reduction in PSD after surgery, with a 2-sided α = .05 and 80% power; 164 patients were needed. Considering the possibility of loss to follow-up or consent withdrawals, 184 patients were included in this trial.

Statistical analysis was performed with SPSS, version 21.0 (IBM SPSS). The normal distribution of the variables was examined using the Kolmogorov-Smirnov test. Continuous data were presented as mean (SD) and compared using the unpaired, 2-tailed t test if distributed normally. Data that were not normally distributed were reported as median (IQR) and analyzed using the Mann-Whitney test. Categorical variables were reported as number (%) and compared using χ² or Fisher exact test, as appropriate.

The results were analyzed using the per protocol principle because there was 1 incomplete piece of information. A logistic regression model was used to assess the potential risk factors associated with PSD. Two-sided P < .05 was considered to be statistically significant.

Results

A total of 200 female patients were assessed for eligibility, and 16 patients were excluded based on the exclusion criteria. There was 1 patient with data loss in the control group on the third
postoperative day (Figure 1). In total, 183 patients were randomized into 2 groups: control group (n = 91; median [IQR] age, 45 [35-49] years) and esketamine group (n = 92; median [IQR] age, 43 [32-49] years) (Table 1).

The demographic data in terms of age, body mass index, ASA classification, surgery type (hysterectomy or myomectomy), preexisting medical conditions, smoking status, and drinking status were similar in both groups. Furthermore, there were no significant differences between the 2 groups for preoperative HADS scores for anxiety and depression, PSQI for sleep disorder, and NRS and AIS scores for sleep quality (Table 1).

Surgery or anesthesia duration, infusion volume, estimated blood loss, and urine output were not different between the 2 groups. The median (IQR) consumption of intraoperative remifentanil was significantly lower in the esketamine group than in the control group (0.14 [0.12-0.16] vs 0.15 [0.13-0.17] μg/kg/min; P = .003). The esketamine group had a longer median (IQR) laryngeal mask removal time (14 [8-20] vs 10 [8-14] minutes; P = .01) and time in the postanesthesia care unit (36 [32-40] vs 32 [30-34] minutes; P < .001) than the control group (Table 1 in Supplement 2).

The median (IQR) NRS (5 [4-5] vs 5 [5-6]; P < .001) and AIS (2 [2-3] vs 3 [2-6] points; P = .01) subjective sleep quality scores in the esketamine group were significantly lower compared with the control group on POD 1. However, the NRS and AIS scores were not significantly different on POD 3 (Table 2).

The esketamine group had a lower incidence of PSD on POD 1 (22.8% vs 44.0%; odds ratio [OR], 0.38 [95% CI, 0.20-0.72]; P = .002) and POD 3 (7.6% vs 19.8%; OR, 0.33 [95% CI, 0.13-0.84]; P = .02) compared with the control group. Moreover, compared with the preoperative baseline value, the incidence of PSD in the control group did not significantly increase. In contrast, the incidence of PSD in the esketamine group on POD 1 decreased significantly compared with baseline.

### Table 1. Patient Demographic and Baseline Characteristics*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control group (n = 91)</th>
<th>Esketamine group (n = 92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR), y</td>
<td>45 (35-49)</td>
<td>43 (32-49)</td>
</tr>
<tr>
<td>Height, median (IQR), cm</td>
<td>160 (158-163)</td>
<td>160 (158-163)</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>23.8 (21.9-26.0)</td>
<td>23.2 (21.2-26.0)</td>
</tr>
<tr>
<td>ASA Physical Status Classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>54 (59.3)</td>
<td>58 (63.0)</td>
</tr>
<tr>
<td>II</td>
<td>35 (38.5)</td>
<td>32 (34.8)</td>
</tr>
<tr>
<td>III</td>
<td>2 (2.2)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Surgery type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myomectomy</td>
<td>47 (51.6)</td>
<td>47 (51.1)</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>44 (48.4)</td>
<td>45 (48.9)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>10 (10.9)</td>
<td>11 (12.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>15 (16.5)</td>
<td>12 (13.0)</td>
</tr>
<tr>
<td>Anemia</td>
<td>28 (30.8)</td>
<td>32 (34.8)</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>4 (4.4)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Liver disease</td>
<td>4 (4.4)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Kidney disease</td>
<td>2 (2.2)</td>
<td>3 (3.3)</td>
</tr>
<tr>
<td>Drinking status</td>
<td>5 (5.5)</td>
<td>4 (4.3)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>3 (3.3)</td>
<td>4 (4.3)</td>
</tr>
<tr>
<td>PSQI, median (IQR)</td>
<td>3 (3-4)</td>
<td>3 (3-4)</td>
</tr>
<tr>
<td>HADS-A score, median (IQR)</td>
<td>7 (5-8)</td>
<td>7 (5-6)</td>
</tr>
<tr>
<td>HADS-D score, median (IQR)</td>
<td>3 (2-4)</td>
<td>3 (2-4)</td>
</tr>
<tr>
<td>Sleep quality, median (IQR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIS score</td>
<td>3 (2-6)</td>
<td>3 (2-6)</td>
</tr>
<tr>
<td>NRS score</td>
<td>5 (4-6)</td>
<td>5 (5-6)</td>
</tr>
</tbody>
</table>

* Data presented as median (IQR) were compared using the Mann-Whitney test. Data reported as the number of patients (%) were compared using the Pearson χ² test or Fisher exact test.
There were no differences in HADS-A and HADS-D scores on POD 1 and POD 3 (Table 2 and Figure 2).

There were no significant differences in VAS scores for pain at rest at 24 hours and 48 hours after surgery. However, the median (IQR) VAS scores for movement were significantly lower in the esketamine group vs control group at 24 hours (3 [3-4] vs 4 [3-5] points; \(P < .001\)) and 48 hours (2 [2-3] vs 3 [2-3] points; \(P = .002\)) after surgery. The median (IQR) hydromorphone consumption in the first 24 hours after surgery (3.0 [2.8-3.3] mg vs 3.2 [2.9-3.4] mg; \(P = .04\)) and total consumption 48 hours after surgery (5.9 [5.5-6.5] mg vs 6.1 [5.7-6.7] mg; \(P = .13\)) were lower in the esketamine group than in the control group (eTable 2 in Supplement 2).

The incidence of postoperative vomiting and nausea, dizziness, itching, and nightmare was not significantly different between the 2 groups. Only 1 patient reported having a nightmare (eTable 3 in Supplement 2).

Multivariable logistic regression was used to explore the risk factors associated with PSD, and these were found to include preoperative depression and anxiety scores (HADS-D: OR, 1.31 [95% CI, 1.01-1.70]; HADS-A: OR, 1.67 [95% CI, 1.04-2.80]), duration of anesthesia (OR, 1.04; 95% CI, 1.00-1.08), and postoperative pain scores (OR, 1.92; 95% CI, 1.24-2.96) (Figure 3).

**Table 2. Sleep Quality, Anxiety, and Depression Scores on Postoperative Days (PODs) 1 and 3**

<table>
<thead>
<tr>
<th>POD 1</th>
<th>Median (IQR)</th>
<th>Control group (n = 91)</th>
<th>Esketamine group (n = 92)</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIS score</td>
<td>3 (2-6)</td>
<td>2 (2-3)</td>
<td>.01</td>
<td></td>
</tr>
<tr>
<td>NRS score</td>
<td>5 (5-6)</td>
<td>5 (4-5)</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>PSD, No. (%)</td>
<td>40 (44.0)</td>
<td>21 (22.8)</td>
<td>.002</td>
<td></td>
</tr>
<tr>
<td>HADS-A score</td>
<td>5 (4-6)</td>
<td>5 (4-6)</td>
<td>.71</td>
<td></td>
</tr>
<tr>
<td>HADS-D score</td>
<td>2 (2-3)</td>
<td>2 (2-3)</td>
<td>.43</td>
<td></td>
</tr>
<tr>
<td>POD 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIS score</td>
<td>3 (2-3)</td>
<td>2 (2-3)</td>
<td>.06</td>
<td></td>
</tr>
<tr>
<td>NRS score</td>
<td>4 (4-5)</td>
<td>4 (4-5)</td>
<td>.05</td>
<td></td>
</tr>
<tr>
<td>PSD, No. (%)</td>
<td>18 (19.8)</td>
<td>7 (7.6)</td>
<td>.02</td>
<td></td>
</tr>
<tr>
<td>HADS-A score</td>
<td>4 (4-5)</td>
<td>4 (3-5)</td>
<td>.68</td>
<td></td>
</tr>
<tr>
<td>HADS-D score</td>
<td>2 (2-2)</td>
<td>2 (2-3)</td>
<td>.75</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 2. Incidence of Postoperative Sleep Disturbance (PSD) on Preoperative Day 1, Postoperative Day 1, and Postoperative Day 3**

* Abbreviations: AIS, Athens Insomnia Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; NRS, numeric rating scale; PSD, postoperative sleep disturbance.

* Data presented as median (IQR) were compared using the Mann-Whitney test. Data reported as the number of patients (%) were compared using the Pearson \(\chi^2\) test or Fisher exact test.
Discussion

The main findings of this trial were as follows. First, postoperative sleep quality and PSD in the esketamine group were significantly lower compared with the control group, suggesting that esketamine can prevent poor postoperative sleep quality and PSD in patients who underwent gynecological laparoscopic surgery. Second, esketamine infusion did not alter the depression and anxiety scores from before the surgery because the scores were low after surgery. There were no significant differences in VAS scores for pain at rest. In contrast, the esketamine group had significantly lower VAS scores for pain on movement. Moreover, esketamine significantly attenuated hydromorphone consumption in the first 24 hours after surgery. Third, multivariable logistic regression showed that preoperative depression and anxiety scores, duration of anesthesia, and postoperative pain scores were all risk factors for PSD. Esketamine had a prophylactic effect against poor postoperative sleep quality and PSD in patients after surgery.

Postoperative sleep disturbance occurs frequently in older patients undergoing major surgery, whereas its incidence in patients undergoing gynecological surgery has increased to 31.4%,23 which is similar to findings in the present trial (44.0% in the control group on POD 1). Specifically, we found that esketamine significantly decreased the PSD incidence from 44.0% to 22.8% on POD 1 and from 19.8% to 7.6% on POD 3. A recent study reported that a subanesthetic dose (0.5-0.75 mg/kg) of (R,S)-ketamine produced an antidepressant effect and better sleep among patients in the intensive care unit.25 Collectively, these data suggest that perioperative esketamine infusion has a prophylactic effect on PSD after surgery.

Pain is a leading cause of PSD in patients after surgery.8 In this trial, the VAS score on movement in the esketamine group was lower compared with the control group. The esketamine group had significantly reduced opioid consumption compared with the control group. Given the analgesic properties of esketamine, the effect of esketamine on postoperative sleep quality and PSD may be associated with the reduction of opioid consumption in patients who underwent gynecological laparoscopic surgery. However, the association between perioperative opioid consumption and PSD development is currently contradictory.26-28

Multivariable logistic analysis showed that preoperative depression and anxiety scores, duration of anesthesia, and postoperative pain scores were associated with the occurrence of PSD, a finding that was in agreement with the results of previous studies.29,30 Poor sleep quality is often seen in older adults, whereas depression and anxiety are both psychiatric risk factors for PSD development.8 Thus, it is possible that anesthesia duration is a risk factor for PSD and that anesthetics, such as isoflurane, sevoflurane, and propofol, have a hypnotic function but are associated with PSD development.

The underlying mechanisms of the prophylactic effect of esketamine on postoperative sleep quality and PSD are currently unclear. After surgery, patients often experience an increase in proinflammatory cytokines, endothelial dysfunction, glycocalyx damage, and activation of neutrophils,31,32 resulting in PSD. Thus, the anti-inflammatory effect of esketamine may contribute

---

**Figure 3. Forest Plot of Factors Analyzed for Association With Incidence of Postoperative Sleep Disturbance in Multivariable Logistic Regression**

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postoperative pain score</td>
<td>1.92 (1.24-2.96)</td>
<td>.004</td>
</tr>
<tr>
<td>Preoperative HADS-D score</td>
<td>1.31 (1.01-1.70)</td>
<td>.04</td>
</tr>
<tr>
<td>Preoperative HADS-A score</td>
<td>1.67 (1.04-2.80)</td>
<td>.03</td>
</tr>
<tr>
<td>Duration of surgery, per min</td>
<td>0.97 (0.94-1.01)</td>
<td>.14</td>
</tr>
<tr>
<td>Duration of anesthesia, per min</td>
<td>1.04 (1.00-1.08)</td>
<td>.03</td>
</tr>
<tr>
<td>Age, per y</td>
<td>1.03 (0.99-1.08)</td>
<td>.10</td>
</tr>
<tr>
<td>Esketamine use</td>
<td>0.29 (0.13-0.64)</td>
<td>.002</td>
</tr>
</tbody>
</table>

HADS-D indicates Hospital Anxiety and Depression Scale-Anxiety; HADS-A, Hospital Anxiety and Depression Scale-Depression; OR, odds ratio.
to its prophylactic effect on PSD. Accumulating evidence suggests that (R,S)-ketamine can modulate circadian rhythms by regulating clock genes.21,33,34 Therefore, it is likely that the beneficial effect of esketamine on PSD is related to the modulation of the circadian rhythm system. Nonetheless, further studies are needed to confirm the role of circadian rhythms in the prophylactic effect of esketamine on PSD.

Bonaventura et al35 reported that, in addition to NMDAR (Kᵢ = 0.8 μM), esketamine has a moderate affinity (Kᵢ = 7 μM) with the μ-opioid receptor. Thus, it is reasonable that the esketamine group had lower consumption of intraoperative remifentanil, a short-acting μ-opioid agonist. Furthermore, it is likely that both NMDAR and μ-opioid receptor play a role in the prophylactic effect of esketamine on PSD after surgery.36 Further studies on opioid receptor antagonists are needed to ascertain the role of the opioid receptor in the prophylactic effect of esketamine on PSD.

Limitations
This study has some limitations. First, there was a change in methods after trial commencement; one of the inclusion criteria changed from ASA I to II to ASA I to III compared with that in the registration protocol in the Chinese Clinical Trial Registry, but only 4 patients who were evaluated to have ASA III were included to reduce study time and were divided into 2 groups equally (2 in the esketamine group, 2 in the control group). Second, this trial was conducted in a single center, and thus multicenter studies are needed. Third, biological samples, such as blood and feces, were not collected; these samples could have helped determine the possible mechanism behind the beneficial effect of esketamine on PSD. Furthermore, there was no bispectral index monitoring during the operation in this trial because the association between ketamine-induced anesthesia and bispectral index was not high.37 Fourth, polysomnography and electroencephalography were not used to analyze the sleep quality among patients due to the complexity of monitoring, particularly in a trial with a large sample size.

Conclusions
The results of this placebo-controlled randomized clinical trial revealed that intraoperative esketamine infusion improved the incidence of PSD in patients who underwent gynecological laparoscopic surgery. Further studies with a larger sample size are needed to confirm the prophylactic effect of esketamine on PSD.
Critical revision of the manuscript for important intellectual content: Wang, Jin-Jin Yang, Yue, Hashimoto, Jian-Jun Yang.


Obtained funding: Wang, Jian-Jun Yang.

Administrative, technical, or material support: Qiu, Jian-Jun Yang.

Supervision: Qiu, Hashimoto, Jian-Jun Yang.

Conflict of Interest Disclosures: Dr Hashimoto reported receiving personal fees from Abbott, Meiji Seika Pharma, and Seikagaku Corporation; receiving grants from Sumitomo Pharma, Taisho, Otsuka, Murakami Farm, and Perception Neuroscience; and being the inventor with filed patent applications for “The use of R-ketamine in the treatment of psychiatric diseases,” “(S)-norketamine and salt thereof as pharmaceutical;” “R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder;” “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases;” “R-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder;” and “TGF-β1 in the treatment of depression” by Chiba University outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by grant 82171189 (Dr Jian-Jun Yang) and grant 81901139 (Dr Wang) from the National Natural Science Foundation of China and by grant CXJD2019008 from The Programme of Subject Innovation of Universities in Henan Province (Dr Jian-Jun Yang).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

REFERENCES
10. Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of ketamine: beyond the NMDA receptor. Mol Psychiatry. 2022;27(1):559-573. doi: 10.1038/s41380-021-01121-1


**SUPPLEMENT 1.**

Trial Protocol

**SUPPLEMENT 2.**

eTable 1. Perioperative Data
eTable 2. Pain Scores and Opioid Consumption at 24 h and 48 h Postoperatively
eTable 3. Postoperative Complications on POD 1 and 3

**SUPPLEMENT 3.**

Data Sharing Statement